AbCellera Biologics (ABCL) Aandelenoverzicht
AbCellera Biologics Inc. houdt zich bezig met het ontdekken en ontwikkelen van geneesmiddelen op basis van antilichamen voor indicaties met een onbeantwoorde medische behoefte in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
ABCL Community Fair Values
Create NarrativeSee what 99 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbCellera Biologics Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$5.31 |
| 52 Week Hoogtepunt | US$8.44 |
| 52 Week Laag | US$2.75 |
| Bèta | 1.15 |
| 1 maand verandering | -28.05% |
| 3 maanden verandering | 27.64% |
| 1 Jaar Verandering | 3.91% |
| 3 jaar verandering | -30.95% |
| 5 jaar verandering | -65.00% |
| Verandering sinds IPO | -90.98% |
Recent nieuws en updates
Narratiefupdate • Jul 09
ABCL: Jazz Deal And Menopause Program Will Support A Stronger Outlook
The analyst fair value estimate for AbCellera Biologics has been raised from $12.00 to $13.00 as analysts point to the new Jazz Pharmaceuticals agreement, recent rating upgrades, and a more constructive view on the company's long term earnings potential, despite lower modeled revenue growth and a higher future P/E assumption. Analyst Commentary Bullish analysts covering AbCellera Biologics are highlighting the recent agreement with Jazz Pharmaceuticals as an important proof point for the company’s partnership model and revenue opportunity.
Narratiefupdate • Jun 25
ABCL: Menopause Phase 2 Progress Will Shape Future Upside Potential
Analysts have lifted their price target on AbCellera Biologics by $1, citing recent bullish coverage and views that the company’s profile compares favorably with certain peers as key reasons for the change. Analyst Commentary Recent research on AbCellera Biologics points to a generally positive tone, with several bullish initiations and a modest price target increase that together shape how analysts are thinking about the stock’s valuation, growth potential, and execution risks.Recent updates
Narratiefupdate • Jul 09
ABCL: Jazz Deal And Menopause Program Will Support A Stronger Outlook
The analyst fair value estimate for AbCellera Biologics has been raised from $12.00 to $13.00 as analysts point to the new Jazz Pharmaceuticals agreement, recent rating upgrades, and a more constructive view on the company's long term earnings potential, despite lower modeled revenue growth and a higher future P/E assumption. Analyst Commentary Bullish analysts covering AbCellera Biologics are highlighting the recent agreement with Jazz Pharmaceuticals as an important proof point for the company’s partnership model and revenue opportunity.Narratiefupdate • Jun 25
ABCL: Menopause Phase 2 Progress Will Shape Future Upside Potential
Analysts have lifted their price target on AbCellera Biologics by $1, citing recent bullish coverage and views that the company’s profile compares favorably with certain peers as key reasons for the change. Analyst Commentary Recent research on AbCellera Biologics points to a generally positive tone, with several bullish initiations and a modest price target increase that together shape how analysts are thinking about the stock’s valuation, growth potential, and execution risks.Seeking Alpha • Jun 17
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
Summary AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions. I initiate my coverage of AbCellera with a “Buy” rating, viewing it as an asymmetric, catalyst-driven bet for investors who can tolerate binary risk. Read the full article on Seeking AlphaNarratiefupdate • Jun 10
ABCL: Menopause Phase 2 Progress Will Support Future Margin Expansion
The analyst price target on AbCellera Biologics has been raised by $1. Analysts cite updated fair value estimates, a slightly lower discount rate, revised revenue growth expectations, and a very large projected future P/E multiple as key drivers of the change.
Narratiefupdate • May 26
ABCL: GPCR Platform Progress And Upcoming Women’s Health Data Will Drive Upside
Analysts lifted their price target on AbCellera Biologics by $1, citing recent bullish initiations and research that view the company’s profile as increasingly attractive relative to selected peers. Analyst Commentary Recent Street research on AbCellera Biologics highlights a mix of optimism and caution, with several firms updating their views and price targets in light of the company’s current positioning and peer comparisons.Analyse-artikel • May 14
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
AbCellera Biologics Inc. ( NASDAQ:ABCL ) investors will be delighted, with the company turning in some strong numbers...Narratiefupdate • May 06
ABCL: Platform And Partnerships Will Support Future Upside From GPCR Pipeline Progress
The analyst price target for AbCellera Biologics has shifted to $7.00, with analysts pointing to updated assumptions around the discount rate, revenue growth, profit margins, and a very large future P/E multiple. This view is supported by recent bullish Street coverage that frames the company as increasingly attractive relative to certain peers.Narratiefupdate • Apr 20
ABCL: Platform And Partnerships Will Support Future Upside Potential
Analysts have adjusted their price target on AbCellera Biologics to $7.00. The change reflects updated assumptions around revenue trends, profit margins, discount rates, and future P/E, supported by recent research that takes a bullish view on the stock.Narratiefupdate • Apr 06
ABCL: Menopause Phase 2 Progress Will Support Future Upside Potential
Analysts maintained their $7.00 price target for AbCellera Biologics, citing only very small adjustments to assumptions around discount rate, revenue trends, profit margin, and future P/E as the basis for keeping their overall valuation view steady. What's in the News AbCellera Biologics has started dosing patients in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narratiefupdate • Mar 22
ABCL: Menopause Trial Progress Will Drive Future Share Price Upside
Analysts have trimmed their price targets on AbCellera Biologics to $7.00, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple that together point to a more cautious outlook on how quickly the business may scale. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narratiefupdate • Mar 08
ABCL: Patent Settlement And Menopause Trial Will Support A Stronger Outlook
Analysts have lowered their price target on AbCellera Biologics from $15.88 to $12.00, reflecting updated views on fair value, revenue growth expectations, and future P/E assumptions. What's in the News The first patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narratiefupdate • Feb 22
ABCL: Menopause Phase 2 Progress And Bruker Settlement Will Support Future Margins
Analysts have maintained their $9.83 price target on AbCellera Biologics, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which they view as collectively balanced at this stage. What's in the News AbCellera began dosing patients in the Phase 2 portion of its ongoing Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narratiefupdate • Feb 08
ABCL: Clinical Progress And Royalty Deal Will Drive Future Share Price Upside
Analysts have reduced their price target on AbCellera Biologics, citing updated assumptions that incorporate higher expected revenue growth and profit margins, partially offset by a lower projected future P/E multiple. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narratiefupdate • Jan 24
ABCL: Phase 2 Menopause Trial Progress Will Support Future Profit Margins
Analysts have trimmed their price target on AbCellera Biologics to US$9.83, reflecting slightly lower discount rate assumptions, a modestly higher long term profit margin outlook, and a small adjustment to future P/E expectations. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narratiefupdate • Jan 08
ABCL: Patent Settlement Cash Flows Will Support A Stronger Future Outlook
Analysts have trimmed their implied fair value estimate for AbCellera Biologics from about US$17.00 to roughly US$15.88, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News AbCellera reached a global settlement and patent license agreement with Bruker Corporation, resolving ongoing patent litigation between the two companies (Key Developments).Narratiefupdate • Dec 14
ABCL: Higher Future Earnings Multiple Will Drive Strong Share Price Upside
Analysts have raised their price target on AbCellera Biologics by approximately 40 percent to reflect a higher fair value estimate of around 7 dollars per share. They cite expectations for modestly slower revenue growth, offset by improved profit margins and a richer future earnings multiple.Narratiefupdate • Nov 29
ABCL: Upcoming Clinical Trial Results Will Drive Future Profit Margins Higher
Analysts have adjusted their price target for AbCellera Biologics slightly downward from $10.20 to $9.83 per share. This change reflects more conservative expectations around future revenue growth and profit margins.Narratiefupdate • Nov 15
ABCL: Upcoming Clinical Trial Results Are Expected To Drive Profit Margins Higher
Analysts have raised their price target for AbCellera Biologics from $9.33 to $10.20 per share, citing improved profit margin forecasts even though revenue growth expectations have slightly moderated. What's in the News AbCellera Biologics has begun dosing the first participants in a Phase 1 clinical trial for ABCL575, an investigational antibody therapy aimed at treating moderate to severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions (Key Developments).Nieuw narratief • May 18
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules.Analyse-artikel • May 15
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates
The latest analyst coverage could presage a bad day for AbCellera Biologics Inc. ( NASDAQ:ABCL ), with the analysts...Seeking Alpha • Apr 17
AbCellera: Attractively Priced But A Catalyst Is Needed
Summary AbCellera's stock remains under pressure due to a shift towards internal development, which has reduced revenue and increased cash burn. AbCellera retains a large cash position, though, giving it a multi-year runway in which to demonstrate the merits of its platform. AbCellera's low enterprise value suggests that investors are either skeptical of the company's platform or ignoring its cash position. A more favorable macro environment and clinical success will likely be needed before AbCellera's stock moves meaningfully higher. Read the full article on Seeking AlphaSeeking Alpha • Mar 15
AbCellera: Burning Cash, Searching For 'Blockbusters'
Summary AbCellera's revenues plummeted post-COVID antiviral sales, leading to a significant net loss and an 85% drop in share price, now at ~$2.5. The company is pivoting to develop its own drug pipeline, with ABCL635 and ABCL575 in late-preclinical stages, targeting metabolic and inflammatory conditions. Financially, AbCellera has ~$840 million in liquidity, but its market cap is lower than its cash reserves, reflecting skepticism about its assets. The company's future hinges on successfully developing a blockbuster drug, with key catalysts not expected until 2026, making its current valuation a gamble. Read the full article on Seeking AlphaSeeking Alpha • Dec 23
AbCellera Biologics: Still A Concept Stock
Summary Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet. An updated analysis around AbCellera Biologics follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Nov 07
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
It's shaping up to be a tough period for AbCellera Biologics Inc. ( NASDAQ:ABCL ), which a week ago released some...Seeking Alpha • Oct 14
AbCellera: A Platform To Pipeline Transition
Summary AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset. Read the full article on Seeking AlphaSeeking Alpha • Aug 23
AbCellera: A Waiting Game With High Uncertainty
Summary AbCellera’s Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company’s net loss widened to $36.9 million due to increased R&D expenses. AbCellera’s cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million. The number of molecules in clinical trials increased from nine to 14 within a year. A "hold" recommendation is maintained due to the speculative and high-risk nature of AbCellera’s business. Read the full article on Seeking AlphaAnalyse-artikel • May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • May 16
AbCellera: Cash Providing Shelter From Market Weakness
Summary AbCellera Biologics is a drug discovery company focused on developing antibody therapies. While the company has developed a technology platform that is open to customers, the current market environment has accelerated its shift towards advancing internal programs. This move should allow the company to capture more value in the long run, but it is depressing revenue and increasing cash burn at the moment. AbCellera's large cash balance will safely see it through this current period, but financial conditions will likely need to ease for the stock to rebound. Read the full article on Seeking AlphaSeeking Alpha • Feb 28
AbCellera: Victim Of Its Own Success
Summary AbCellera Biologics has faced declining royalty revenues, along with decreased demand for R&D services due to the current financing environment. As a result, AbCellera is shifting focus towards advancing internal programs and partner programs with more potential downstream value. The combination of declining revenue and rising costs is pressuring the stock, even as the underlying business appears to be steadily progressing. This situation appears to have been exacerbated by the company's success during the pandemic leading to over-inflated investor expectations, and subsequently, disappointment. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
AbCellera Biologics: Continuing To Expand Partnerships
Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's partner pipeline is primarily very early-stage candidates. An updated analysis around AbCellera Biologics follows in the paragraphs below. Read the full article on Seeking AlphaRendement voor aandeelhouders
| ABCL | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | -17.9% | 0.8% | -1.0% |
| 1Y | 3.9% | 11.2% | 14.7% |
Rendement versus industrie: ABCL presteerde slechter dan de US Life Sciences -sector, die het afgelopen jaar een rendement van 11.2 % opleverde.
Rendement versus markt: ABCL presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 14.7 % opleverde.
Prijsvolatiliteit
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 13.7% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van ABCL is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 14% ) van ABCL is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2012 | 562 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. houdt zich bezig met het ontdekken en ontwikkelen van op antilichamen gebaseerde geneesmiddelen voor aandoeningen waarvoor in de Verenigde Staten nog geen adequate behandeling bestaat. Het belangrijkste product van het bedrijf is ABCL635, een niet-hormonaal geneesmiddel dat zich momenteel in een fase 2-klinische studie bevindt voor de behandeling van matige tot ernstige vasomotorische symptomen; en ABCL575, een volledig humaan monoklonaal antilichaam met verlengde halfwaardetijd, dat zich in een fase 1-klinische studie bevindt voor de behandeling van door T-cellen gemedieerde auto-immuunziekten, zoals atopische dermatitis. Het bedrijf heeft een samenwerkings- en licentieovereenkomst op het gebied van onderzoek met Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc voor de ontwikkeling van multispecifieke antilichamen die T-cellen activeren (TCE); en een samenwerkingsovereenkomst met Viking Global Investors & ArrowMark Partners en Biogen Inc. AbCellera Biologics Inc. werd in 2012 opgericht en heeft zijn hoofdkantoor in Vancouver, Canada.
AbCellera Biologics Inc. Samenvatting
| ABCL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.62b |
| Inkomsten(TTM) | -US$143.96m |
| Inkomsten(TTM) | US$79.21m |
20.5x
P/S-verhouding-11.3x
Koers/WinstverhoudingIs ABCL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ABCL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$79.21m |
| Kosten van inkomsten | US$191.00m |
| Brutowinst | -US$111.79m |
| Overige uitgaven | US$32.17m |
| Inkomsten | -US$143.96m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Aug 05, 2026
| Winst per aandeel (EPS) | -0.47 |
| Brutomarge | -141.13% |
| Nettowinstmarge | -181.74% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ABCL op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/26 04:19 |
| Aandelenkoers aan het einde van de dag | 2026/07/24 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
AbCellera Biologics Inc. wordt gevolgd door 13 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Robert Wasserman | Benchmark Company |
| Guyn Kim | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |